← All trials
NCT03556228
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 8, 2018
- Primary completion
- Nov 30, 2019
- Completion date
- May 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 54
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- VM Oncology, LLCLead sponsor
- MedAssessmentStudy director
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Appendiceal Neoplasms
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Colonic Neoplasms
- Carcinoma, Adenoid Cystic
- Esophageal Neoplasms
- Gallbladder Neoplasms
- Carcinoma, Hepatocellular
- Leiomyosarcoma
- Lung Neoplasms
- Lymphoma, Non-Hodgkin
- Melanoma
- Mesothelioma
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Sarcoma
- Stomach Neoplasms
- Thymoma
- Uterine Neoplasms
- Leukemia, Myeloid, Acute
- Esthesioneuroblastoma, Olfactory
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.